health Australia
Advocates call for subsidised GLP-1 drugs for PMOS
0.13share
PMOS affects one in eight women.
The Polyendocrine Metabolic Ovarian Syndrome Association of Australia is urging Australia to subsidise GLP-1 medications for people with PMOS. The article also describes current approval, PBS coverage and research issues.
- Polyendocrine Metabolic Ovarian Syndrome Association of Australia
- PMOS
- Australia
- GLP-1 drugs
- Pharmaceutical Benefits Scheme
1 sourceThe GuardianUpdated
Claims
Support what holds up. Dispute what doesn't.
The Polyendocrine Metabolic Ovarian Syndrome Association of Australia is urging GLP-1 drugs to be approved on Australia's Pharmaceutical Benefits Scheme for people with PMOS.
“The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme”
- 0.13share
PMOS affects one in eight women.
“PMOS affects one in eight women.”
PMOS is a lifelong condition for which there is no cure.
“The lifelong condition, for which there is no cure”